BioTuesdays

Category - Markets

Markets

Leerink starts Turnstone Biologics at MP; PT $13

Leerink Partners initiated coverage of Turnstone Biologics (NASDAQ:TSBX) with a “market perform” rating and $13 price target. The stock closed at $11.73 on Aug. 14. “We see potential in Turnstone’s selected tumor...

August 15, 2023
Markets

Ladenburg cuts Salarius to neutral; removes PT

Ladenburg Thalmann downgraded Salarius Pharmaceuticals (NASDAQ:SLRX) to “neutral” from “buy” and removed its price target after the company disclosed it is exploring strategic alternatives and implement cost-cutting...

August 11, 2023
Quanterix Logo
Markets

Leerink ups Quanterix to OP; PT to $30

Leerink Partners upgraded Quanterix (NASDAQ:QTRX) to “outperform” from “market perform” and raised its price target to $30 from $25, citing strong evidence for its assays redevelopment effort. Analyst Puneet Souda...

August 8, 2023
Markets

Cantor starts Health Catalyst at OW; PT $16

Cantor Fitzgerald launched coverage of Health Catalyst (NASDAQ:HCAT) with an “overweight” rating and price target of $16, representing a 2024 enterprise value/revenue multiple of 2.3 times. The stock closed at $14.03 on...

August 1, 2023
Markets

Cantor starts Belite Bio at OW; PT $43

Cantor Fitzgerald launched coverage of Belite Bio (NASDAQ:BITR) with an “overweight” rating and a 12-month price target of $43. Belite listed its ADSs on NASDAQ in April 2022; they closed at $20.55 on July 27. Belite...

July 28, 2023
Aeglea-Bio-Logo
Markets

Stifel starts Aeglea Bio at buy; PT 90 cents

Stifel initiated coverage of Aeglea BioTherapeutics (NASDAQ:AGLE) with a “buy” rating and price target of 90 cents. The stock closed at 59 cents on July 24. Aeglea is a biotechnology company that is now focused on the...

July 25, 2023
Markets

Cantor starts LifeMD at OW; PT $7

Cantor Fitzgerald initiated coverage of LifeMD (NASDAQ:LFMD) with an “overweight” rating and price target of $7. The stock closed at $3.53 on July 20. “We see LifeMD as an undervalued, below-the-radar growth story in...

July 21, 2023